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Sulindac (SLD) exhibits both the highest inhibitory activity towards human aldose reductase (AR)
among popular non-steroidal anti-inﬂammatory drugs and clear beneﬁcial clinical effects on Type
2 diabetes. However, the molecular basis for these properties is unclear. Here, we report that SLD
and its pharmacologically active/inactive metabolites, SLD sulﬁde and SLD sulfone, are equally effec-
tive as un-competitive inhibitors of AR in vitro. Crystallographic analysis reveals that p–p stacking
favored by the distinct scaffold of SLDs is pivotal to their high AR inhibitory activities. These results
also suggest that SLD sulfone could be a potent lead compound for AR inhibition in vivo.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Sulindac (SLD), a widely used non-steroidal anti-inﬂammatory
drug (NSAID) that is a potent non-selective inhibitor of cyclooxy-
genases (COXs) [1], has shown convincing evidence of beneﬁcial
pharmacological effects on Type 2 diabetic complications in ani-
mal experiments and in clinical trials [2–9]. The inhibition of al-
dose reductase (AR, EC 1.1.1.21) by SLD has been proposed to play
an important role in its diabetic beneﬁts [3,4,7,10].
AR, the ﬁrst and rate-limiting enzyme in the polyol pathway
that catalyzes NADPH-dependent reduction of glucose to sorbitol,
has long been a drug target for Type 2 diabetic complications
[11–16]. In vitro studies have shown that SLD exhibits the highest
inhibitory activity towards AR among all tested NASIDs [17]. In
addition, in vivo experiments have demonstrated that SLD signif-
icantly suppresses sorbitol accumulation in red blood cells and in
sciatic nerves, and reduces fructose and sorbitol dehydrogenase
levels in diabetic rat models [3,4,10].
As a prodrug, SLD is reversibly metabolized in the liver or the
intestine to pharmacologically active SLD sulﬁde, which inhibitschemical Societies. Published by E
c; SLDs, sulindac and its two
drugs; COXs, cyclooxygenases
ng).COXs, and irreversibly metabolized in the liver to SLD sulfone,
which does not inhibit COXs [18]. In addition to their different
responses to COXs, SLD and the two metabolites (SLDs) respond
signiﬁcantly differently to COX-independent off-target proteins.
For example, SLD sulﬁde potentially modulates c-secretase func-
tion and directly inhibits 5-lipoxygenase, whereas neither SLD nor
SLD sulfone interacts with those enzymes [19–22]. Considerations
of the toxicity resulting from non-selective COX inhibition (sup-
pression of prostaglandin synthesis) and the different responses
of COXs to SLDs suggest that an SLD derivative with the high
in vitro AR inhibitory activity of SLD but without COX inhibition
could be more promising for diabetic or other AR related medical
therapies. Derivatives of SLD sulfone have been synthesized as
antineoplastic agents with little or no inhibition of COXs activity
[23,24], but the AR inhibition mechanism of SLD at the molecular
level remains unknown, and it is unclear whether the metabolites
are responsible for the inhibition of AR by SLD.
In this study, using detailed enzyme kinetics and x-ray crys-
tallography analysis, we report that sulindac and its metabolites
are strong un-competitive AR inhibitors in vitro. Our results
clearly support the physiological mechanism of inhibition of
AR by SLD, and should lead to a better understanding of SLDs’
off-target effects. The ligand-protein interactions responsible for
its high inhibition highlight the promise of SLD sulfone as a po-
tent AR inhibitor lead compound, and provide information that
is relevant for future optimization.lsevier B.V. All rights reserved.
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2.1. Materials
6His-tagged recombinant human AR was overexpressed in
Escherichia coli and puriﬁed as described previously [25]. Sulindac,
sulindac sulﬁde, sulindac sulfone, tolmetin, indomethacin, epalre-
stat and NADP+ were purchased from Sigma–Aldrich. All other
chemicals were of reagent grade.
2.2. Enzyme assay and determination of the inhibition constants
In vitro enzyme assays were performed according to the meth-
ods reported by other laboratories [25]. Brieﬂy, enzyme activity
was measured by monitoring the rate of disappearance of NADPH
in 1 ml of 0.1 M phosphate buffer (pH 6.2) containing 0.2 mM
NADPH, 5 mM D,L-glyceraldehyde, 0.2 M lithium sulfate, 1% DMSO
and various concentrations of an inhibitor. IC50 values were deter-
mined by non-linear regression analysis of a plot of V/V0 versus log
inhibitor concentration. The inhibition modality and the values of
the inhibition constant (Ki) were determined by ﬁtting directly
and globally all the plots of velocity versus glyceraldehyde at sev-
eral ﬁxed inhibitor concentrations to the untransformed equations
for uncompetitive inhibition or by Lineweaver–Burk double reci-
procal plots and Dixon plots.
2.3. Crystallization, data collection and structure determination
AR crystals were grown by the hanging-drop vapor-diffusion
method in 10 ll drops. The drops containing 25 mg/ml AR with
two equivalents of NADP+ and 7.5% PEG 6000 were equilibrated
against a well containing 1 ml of 120 mM ammonium citrate (pH
5.0), 20% (m/V) PEG 6000. Crystals were then transferred to an
inhibitor saturated solution containing 25% (m/V) PEG 6000,
50 mM ammonium citrate (pH 5.0) and 5% (V/V) DMSO.
X-ray diffraction data were collected at 100 K on an in-house
Oxford Diffraction Xcalibur Nova diffractometer. The data were
processed using the program CrysAlis Pro. The structures were
solved by molecular replacement with MOLREP by using the AR
structure (PDB Code: 1US0) as a search model [26]. Structures ofTable 1
X-ray diffraction data processing and reﬁnement statistics.
Data collection SLD SLD sulﬁde
Wavelength (Å) 1.5418 1.5418
Temperature (K) 100 100
Resolution (Å) 24.05–1.90 24.75–2.00
Space group P21 P21
Unit cell
a, b, c (Å) 47.15, 66.73, 49.32 47.58, 67.00,
a, b, c () 90.00, 92.10, 90.00 90.00, 91.33,
No. reﬂections 23556 (3020) 21141 (3063
Completeness (%) 97.5 (90.0) 99.5 (100.0)
Rmerge 0.057 (0.16) 0.066 (0.17)
<I/r(I)> 34.7 (6.4) 28.0 (11.5)
Redundancy 6.9 (2.8) 11.0 (8.5)
Rwork/Rfree 0.150/0.201 0.15/0.20
B-factor (all)
Protein 13.38 10.54
Ligand/ion 14.48 10.41
Waters 21.99 18.10
No. atoms
Protein 2566 2547
Ligand/ion 73 72
Waters 414 365
R.m.s. deviations
Bond lengths 0.007 0.007
Bond angles 1.130 1.183
aValues for the highest-resolution shells are given in parentheses.AR in complex with sulindac, sulindac sulﬁde, sulindac sulfone
and tolmetin were built and reﬁned by using Phenix and Coot at
resolution of 1.9, 2.0, 1.9, and 1.8 Å, respectively [27,28]. The coor-
dinates and structure factors have been deposited in the Protein
Data Bank with PDB ID: 3RX3, 3RX4, 3RX2 and 3S3G. All structural
ﬁgures were produced using PyMOL. Data collection, reﬁnement
statistics for all structures are shown in Table 1.
3. Results and discussion
3.1. Biochemical characterization of SLDs as uncompetitive
AR inhibitors
The structures and enzyme kinetic results of the tested com-
pounds are shown in Figs. 1 and 2a, respectively. The double-reci-
procal plot composed of parallel lines with apparently decreased
Vmax and Km as increasing SLD concentration indicate that these
compounds inhibit AR in an uncompetitive manner, which means
SLD may exert their inhibitory effect by binding to the E-NADP+
complex as other negatively charged AR inhibitors [29].
The inhibition constants (Ki)were determined to be 0.458 lMfor
SLD, which is similar to the Ki value of 0.3 lM reported previously
[17], 0.300 lM for SLD sulﬁde and 0.434 lM for SLD sulfone (Figs.
1 and 2b). The similarity of the Ki values of the SLDs strongly
supports theproposal thatAR inhibition is partly or fully responsible
for the pharmacological effects on Type 2 diabetic complications.
These results also imply that SLD sulfone could be used as a useful
in vivo drug probe to determinewhether COXs inhibition is required
for SLD or other NSAIDs’ efﬁcacy in treating diabetic complications.
Furthermore, the likelihood that SLD sulfonewould shownoadverse
effects and/or toxicity resulting from COX inhibition suggests that
this sulfone could be used as a potent AR inhibitor lead.
3.2. The interactions of SLDs with AR revealed by X-ray
crystallographic analysis
Prior research has indicated that negatively charged AR inhibi-
tors, either non-competitive or uncompetitive, bind at the active
site of the AR-NADP+ complex [29–33]. Consistentwith these obser-
vations, SLDs bind to the AR-NADP+ complex as negatively chargedSLD sulfone Tolmetin
1.5418 1.5418
100 100
24.66–1.90 24.66–1.80
P21 P21
49.57 47.19, 67.08, 49.36 47.13, 66.57, 49.29
90.00 90.00, 92.00, 90.00 90.00, 92.00, 90.00
) 24115 (3321) 27263 (3125)
99.1 (94.4) 96.2 (75.8)
0.081 (0.26) 0.093 (0.559)
15.6 (4.1) 15.8 (2.2)
5.6 (3.1) 7.7 (2.5)
0.14/0.20 0.16/0.20
12.18 13.04
11.92 12.35
23.51 23.17
2852 2539
74 67
514 449
0.007 0.008
1.156 1.363
Fig. 1. Chemical formulae and human AR inhibitory activities of tested compounds.
Fig. 2. Kinetics and inhibition constant of recombinant human AR inhibition by SLD. (a) Double reciprocal plots of the initial enzyme velocities versus concentrations of SLD,
L-glyceraldehyde at varying concentrations of SLD (SLD sulﬁde and SLD sulfone give similar results). (b) Dixon plot of SLDs under saturating substrate (DL-glyceraldehyde,
5 mM). X-axis intercepts give out Ki. Error bars are shown (mean ± S.D., n = 3).
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ARwith the indene systempresent in the partly polar anion-binding
pocket, primarily composed of Tyr48, Lys77 and His110, with the
benzene moiety close to Phe122 of the upper hydrophobic portion
formed in large part by Trp219 and Phe122 (Fig. 3a and b).
A schematic representation of theAR/SLD complexbinding pock-
et is shown in Fig. 3c. The carboxylate attached to the indene system
interacts through H-bonds with the OH of Tyr48, the NE1 of His110,
and the NE1 of Trp111, with H-bond distances of 2.9 Å, 2.9 Å, and
3.1 Å, respectively. As observed in other carboxylate-type inhibi-
tor/AR structures, such as IDD594/AR [33], the deprotonated
carboxylate acts as an H-bond acceptor and forms an electrostatic
interaction with the positively charged nicotinamide moiety of
NADP+ (3.3 Å between the oxygen atom of the carboxylate and the
nicotinamide carbon C4 of NADP+). The indene system further forms
a p–p stacking interaction with the side-chain of Trp20 (4.7 Å), and
has van der Waals contacts with the side-chain of Val47 (3.9 Å be-
tween Val47 CG1 and SLD’s F) and Cys298 (4.2 Å between Cys298 S
and -CH3 of indene). The benzenemoiety interacts with the enzyme
via a parallel-displaced p–p stacking to the side chain of Phe122.
Further hydrophobic or van der Waals contacts are formed by the
benzene ring and Leu300 (3.0 Å between Leu300 CD1 and C50),
-SOCH3 functional group in the benzene moiety to Ser302, and the
spacer to the side-chain of Trp219 (4.2 Å between Trp219 CZ3 and
spacer C).
Structurally, these SLDs only differ in the oxidation state of the
sulfur atom (Fig. 1). The additional O atoms of both SLD sulﬁde
(5.0 Å between Ser302 OH and O of –SOCH3) and SLD sulfone (4.4
Å between Ser302 OH and O1 of –SO2CH3, 4.0 Å between Phe122
CB and O2 of –SO2CH3) only form weak van der Waals contacts to
AR. Thus, theoxidation stateof the sulfur atomcontributesvery little
to the binding of SLDs to AR. As a result, these three compounds
exhibit almost equal afﬁnities towards AR.
Usually, selective AR inhibitors (having lower inhibition toward
aldehyde redctase) induce a speciﬁcity pocket formed from differ-
ent rotameric states of Ala299, Leu300, Phe122 and Trp111 [33]. Inthe present case, SLD binds to AR with the speciﬁcity pocket in the
closed state, due to its rigid scaffold, which is indicated by the van
der Waals contacts between the gating residues Trp111 and
Leu300 and a conformation of Leu300 that is quite different from
that of the IDD594-AR structure (Fig. 3d). This structural result
corresponds well with the high inhibition of SLDs towards alde-
hyde redctase [17].
3.3. A unique p–p stacking favored by a distinct scaffold of SLD
is responsible for its high AR inhibition
Previous researchers found that SLD exhibits the greatest inhi-
bition towards AR among common NASIDs [17]. Our in vitro assay
conﬁrms that two analogs of SLD, indomacthin and tolmetin, exhi-
bit signiﬁcantly weaker binding to AR (Fig. 1). To investigate the
molecular basis of this difference, the crystal structure of the tol-
metin/AR/NADP+ ternary complex was determined. As shown in
Figs. 3e and f, the acidic group of tolmetin is located in a position
that is nearly identically to that of SLD, and its pyrrole moiety
superimposes well with the ﬁve-membered ring of the indene
system of SLD. However, the benzene moiety of tolmetin, tends
to Trp219 and Cys298 of the hydrophobic pocket, and forms a
T-shaped p–p stacking with Phe122. According to the deﬁnition
of McGaughey et al. [34], benzene rings of tolmetin and Phe122
make a center-normal angle (h) of 7, with a distance between
the two aromatic centroids Rcen of 5.2 Å, and closest contact car-
bons Rclo of 3.8 Å. In contrast, for the benzene rings of SLD and
Phe122, h (31) is almost the same as the preferred value of parallel
p–p stacking in proteins (30), with Rcen of 4.1 Å and Rclo of 3.4 Å
[34]. The values of h, Rcen and Rclo indicate that the p–p stacking
of SLD-Phe122 is 1.0–0.75 kcal/mol more stable than that of tol-
metin-Phe122 [34]. This energy difference gives a good correlation
with IC50 values for SLD and tolmetin.
The molecular structures of SLD, tolmetin and indomethacin
reveal that the distinct geometry of SLD may facilitate the p–p
stacking (Fig. 1). The conjugated p system of SLD spans the fused
Fig. 3. Binding site pocket of AR in complex with SLDs and tolmetin. (a) SLD (cyan), and (e) tolmetin (green) bound at the active pocket of AR. 2Fo-Fc electron density are
contoured in dark blue at 1.0r. Binding site pocket residues are represented by silver sticks. The benzene moiety of SLDs forms a p–p stacking interaction with Phe122,
highlighted as purple sticks. Hydrogen bonds are indicated as yellow broken lines. (b) Superposition of SLD (cyan), SLD sulﬁde (wheat) and SLD sulfone (slate), (f)
Superposition of SLD (cyan) and tolmetin (green) in complex with AR. Residues are in similar conformations and those of the AR-sulindac complex are shown as silver sticks.
(c) Schematic representation of the binding patterns of SLD (red). Hydrogen bond: black dotted lines, p–p stacking: green wavy line. (d) Superposition of SLD (cyan) and
IDD594 (marine) in complex with AR.
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rigid scaffold. The phenyl group of SLD forms a dihedral angle of
about 51 relative to its ﬁxed fused-ring system. This dihedral
angle is very close to that of the theoretically most stable confor-
mation (60) [35]. For tolmetin, due to the existence of a C=Ogroup, the benzene tends to form an angle of 40 to the plane of
the ﬁve member ring, at the theoretically most stable conformation
[36]. If tolmetin were to adopt the same orientation as SLD, its hex-
agonal ring would clash with the side chain of Phe122. As indicated
by Koch, et al., the consistent position/orientation of Phe122 in
X. Zheng et al. / FEBS Letters 586 (2012) 55–59 59different AR structures implies that Phe122 is a rigid residue [37].
Consequently, tolmetin adopts a different orientation to avoid this
interaction, but still retains some interactions with Phe122, and
exhibits weaker binding afﬁnity to AR than SLD. For indomethacin,
the same interaction still exists and an extra interaction between
its -OCH3 group and Val47 should further restrict the ideal orienta-
tion. Thus the much weaker binding afﬁnity of indomethacin to AR
than SLD is very reasonable.
As the present paper was being prepared for publication, a
structure of AR in complex with SLD was published by Steuber
[38]. Although the two studies are generally in agreement, our pa-
per provides a more detailed enzyme/molecular basis for under-
standing of the AR inhibitory mechanism of sulindac, its
metabolites and its analog tolmetin.
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